carcinoma

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

...ent of locally or regionally advancedsquamous cell carcinoma of the head and neck. ERBITUX as a singleagent is ...patients with recurrent ormetastatic squamous cell carcinoma of the head and neck for whomprior platinum-based therapy has failed. ERBITUX is indicated for the ...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

...sociation with either study drug (basal cell carcinoma and urinary tract infection). The remaining three events consisted of mild injection site erythema (redness) that occurred on the day of the co-injection and resolved within one or two days. As a spreading agent, hyaluronidase has...

Protox Announces Positive Clinical Data from Prostate Cancer Study

...X321 for the treatment of patients with renal cell carcinoma and non-small celllung cancer has been completed. Patient enrollment has beencompleted for a Phase 1 clinical trial evaluating PRX302(PORxin) for the treatment of localized prostate cancer. APhase 1 clinical trial evaluating PRX302 for the treatme...

Researchers Discover Method for Identifying How Cancer Evades the Immune System

...esponding human tumors, eight cases of humanductal carcinoma and 11 cases of colorectal cancer. Remarkably, the researchers found that the immune signatures ofeach of the human breast cancer cases nearly matched that of mice.In all cases, the researchers saw a suppression of CD83 and CD28,two genes that affe...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

...adenoma/carcinomain males and females and of liver carcinoma in females at 500 mg/kg.This dose results in exposures approximately 60 times the humanexposure at the maximum recommended daily adult human dose (MRHD) of100 mg/day based on AUC comparisons. Liver tumors were not observed at150 mg/kg, approximately ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

...adenoma/carcinomain males and females and of liver carcinoma in females at 500 mg/kg.This dose results in exposures approximately 60 times the humanexposure at the maximum recommended daily adult human dose (MRHD) of100 mg/day based on AUC comparisons. Liver tumors were not observed at150 mg/kg, approximately ...

CuraGen Presents Update on Clinical Development Program for Belinostat

...der cancer (SD for 20 cycles),and one patient with carcinoma of unknown primary (SD for 17 cyclesand ongoing). ...ry/borderline low malignant potential(LMP) ovarian carcinoma or advanced platinum resistant ovariantumors The Phase II trial is an open-label study evaluating b...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

...ent of locally or regionally advancedsquamous cell carcinoma of the head and neck. ERBITUX as a singleagent is ...patients with recurrent ormetastatic squamous cell carcinoma of the head and neck for whomprior platinum-based therapy has failed. ERBITUX is indicated for the ...

Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients

...nts. In recurrent and/or metastatic squamous cell carcinoma of thehead and neck (SCCHN) – which is notoriously difficult totreat – first-line Erbitux combined with platinum-basedchemotherapy met the primary endpoint of increasing overallsurvival. This phase III randomized controlled European trial...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

... cancer, primary peritoneal or fallopian tube carcinoma (stage I-IV) or papillary serous cancer of t...stic with cisplatin against human urothelial carcinoma in a preclinical model About US Oncology Research The US Oncology Research Network is an establish...

GSK'S Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

...s of pazopanib inadvanced or metastatic renal cell carcinoma (RCC), ovarian cancerand soft tissue sarcoma (STS)...the growth and spread of tumors. (1,2) Renal cell carcinoma study (Abstract 5031) (3) This ongoing Phase II randomized discontinuation study isevaluating patie...

Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)

...sion, diarrhea, and voice alteration. "Renal cell carcinoma is a chemoresistant disease which hastraditionally been difficult to treat, resulting in poor prognosisfor patients hence these early data are encouraging," commentedProfessor S. Sridhar of the Princess Margaret Hospital Phase IIConsortium, Toronto, ...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

...R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were presented today at the annual meeting of the AmericanSociety of Clinical Oncology in Chicago. Tumor responses were assessed in 112 patients with recurrenthead and neck cancer who received ADVEXIN. O...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

... use of Erbitux in colorectalcancer, squamous cell carcinoma of the head and neck and non-smallcell lung cancer. Merck KGaA, Darmstadt, Germany, licensed theright to market Erbitux outside the US and Canada from ImCloneSystems Incorporated of New York in 1998. In Japan, Merck KGaA hasco-exclusive marketing rig...

Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer

...tedprincipally in colorectal cancer, squamous cell carcinoma of thehead and neck and non-small cell lung cancer. Merck KGaA is also investigating other cancer treatments,including the use of Stimuvax® (formerly referred to as BLP25Liposome Vaccine) in the treatment of non-small cell lung cancer.The vaccin...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

...5-FU/LV, isindicated for the treatment of advanced carcinoma of the colon orrectum. Clinical Safety Considerations Eloxatin(R) should be administered under the supervision of aphysician experienced in the use of cancer chemotherapeuticagents. Appropriate management of therapy and complications is possibleon...

Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients

...or this difficult to treatcancer." Hepatocellular carcinoma is the most common form of liver cancerand is resp... the treatment of patients with advancedrenal cell carcinoma (RCC) who have failed prior interferon-alphaor interleukin-2 based therapy or are considered unsuita...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...coma,hemangioendothelioma, melanoma and renal cell carcinoma with afavorable side effect profile. About Kosan Kosan Biosciences is a biotechnology company advancing two newclasses of anticancer agents through clinical development -- Hsp90(heat shock protein 90) inhibitors and epothilones. Kosan isleveraging ...

Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study

...r second-linetreatment of patients with metastatic carcinoma of the colon orrectum and in combination with carboplatin and paclitaxel for thefirst-line treatment of patients with unresectable, locallyadvanced, recurrent or metastatic non-squamous non-small cell lungcancer (NSCLC). Avastin is a product of Genen...

Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001

...suffering from advanced,hormone-resistant prostate carcinoma responded positively to theVPM4001 therapy. The primary study parameter, the PSA doublingtime, was increased from 63 days to 114 days on average. Thispromising result has a high statistical significance (p=0.0035).VPM4001 also showed an excellent tol...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

...the second-linetreatment of patients with advanced carcinoma of the colon orrectum. In 2004, Eloxatin received ...ents with inoperablelocally advanced squamous cell carcinoma of the head and neck(SCCHN). Important safety information WARNING: Taxotere(R) treatment can cause...

Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

... (ADVEXIN)in patients with recurrent squamous cell carcinoma of the head andneck, Abstract #6057: Poster presentation on Mon., June 4, from1:00 - 5:00 p.m. at McCormick Place by lead author John Nemunaitis,M.D., Mary Crowley Medical Research Center and poster presentationby Robert Sobol, M.D., Introgen Therape...

New Pfizer Oncology Data Across Numerous Cancer Types to be Presented at ASCO

... cell lung (NSCLC), colorectal(CRC) and renal cell carcinoma (RCC) - a type of advanced kidneycancer - will be ...r approved for the treatment ofadvanced renal cell carcinoma (RCC) and gastrointestinal stromaltumor (GIST) after disease progression on or intolerance toimatini...

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

...live call. About Renal Cell Carcinoma Renal cell carcinoma is the most common type of kidney cancer.The Ameri...12,890 people will die from the disease.Renal cell carcinoma accounts for about 90 percent of all kidneytumors. By the time renal cell carcinoma is diagnosed in ...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

...immediate and necessary precursors ofsquamous cell carcinoma and adenocarcinoma of the cervix,respectively. Their detection and removal has been shown to preventcancer; thus, they serve as surrogate markers for prevention ofcervical cancer. Efficacy was assessed in 4 placebo-controlled, double-blind,randomi...

Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented

...tic melanoma (stage III/IV), oradvanced colorectal carcinoma (stage III/IV) as a 7-day continuousinfusion every other week. “The first milestone of the studyhas been achieved, as the maximum tolerated dose was determinedwith this treatment schedule”, explains Hubert Heinrichs,M.D., Ph.D., Chief Med...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

...immediate and necessary precursors ofsquamous cell carcinoma and adenocarcinoma of the cervix,respectively. Their detection and removal has been shown to preventcancer; thus, they serve as surrogate markers for prevention ofcervical cancer. Efficacy was assessed in 4 placebo-controlled, double-blind,randomi...

Gardasil Demonstrates Up to 100% Efficacy

...age and is indicated for the preventionof cervical carcinoma (cervical cancer), high grade cervicaldysplasia CIN2/3 (precancerous cervical lesions), high grade vulvardysplastic lesions VIN 2/3 (precancerous vulvar lesions) andexternal genital warts (condyloma acuminata) caused by HumanPapillomavirus types 6, 1...

Idenix Announces Data Presentations at the 2007 Digestive Disease Week Meeting

... response to outcomes such as hepatocellular carcinoma and decompensated cirrhosis are unknown. About Idenix Idenix Pharmaceuticals, Inc., headquartered in Cambridge, MA, isa biopharmaceutical company engaged in the discovery, developmentand commercialization of drugs for the treatment of human viral a...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

...Mice Ovarian cancer represents the most malignant carcinoma of thefemale genital tract and is often diagnosed only after the diseasehas reached the advanced stage. Currently, primary therapy includessurgery followed by chemotherapy. In preclinical studies, SPI(IRL)-1620 has demonstrated an enhanced efficacy o...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

...tuximab and gemcitabine therapy in humanpancreatic carcinoma xenografts; #4396 Krystal et al. Selectiveinhibition of SCLC growth by the A12 anti-IGF-1R monoclonalantibody correlates with inhibition of Akt.) -- IMC-18F1 (anti-VEGFR-1 MAb) (#4100 Wang et al. Expression ofvascular endothelial growth factor recep...

Viventia biotech reports synergystic effect of its Proxinium antibody in combinaton with chemotherapy and radiation

...rst-linestandard of care therapy for squamous cell carcinoma of the head& neck (SCCHN). The data were presented at the Annual Meetingof the American Association for Cancer Research (AACR), which runsfrom April 14-18, 2007 in Los Angeles, California. Viventia's lead product, Proxinium(TM), is being develop...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

...ent of locally or regionally advancedsquamous cell carcinoma of the head and neck. ERBITUX as a singleagent is ...patients with recurrent ormetastatic squamous cell carcinoma of the head and neck for whomprior platinum-based therapy has failed. ERBITUX is indicated for the ...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

...titis B virus (HBV)-carrying hepatocellular carcinoma (HCC) cell lines," (Abstract #696) during the conference's HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall, Poster Section 28 on Poster Board #19 -- "The histone deacetylase (HDAC) inhibitor PXD101 s...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

...ent of locally or regionally advancedsquamous cell carcinoma of the head and neck. ERBITUX as a singleagent is ...patients with recurrent ormetastatic squamous cell carcinoma of the head and neck for whomprior platinum-based therapy has failed. ERBITUX is indicated for the ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...ents with recurrent and/ormetastatic squamous cell carcinoma of the head and neck (SCCHN).The randomized, multi...ent of locally or regionally advancedsquamous cell carcinoma of the head and neck. ERBITUX as a singleagent is indicated for the treatment of patients with recur...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...entswith recurrent and/or metastatic squamous cell carcinoma of thehead and neck (SCCHN). The randomized, multi...ent of locally or regionally advancedsquamous cell carcinoma of the head and neck. ERBITUX as a singleagent is indicated for the treatment of patients with recur...

One-Third of Patients Discontinue Common Breast Cancer Therapy

...ancer, adjuvant treatment of breast cancer, ductal carcinoma insitu (DCIS), and reduction in breast cancer incidence in high riskwomen. WARNING - For Women with Ductal Carcinoma in Situ (DCIS) andWomen at High Risk for Breast Cancer: Serious and life-threateningevents associated with tamoxifen in the risk red...